Overview

Cardiac Sarcoidosis Randomized Trial

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hypothesize that low dose Prednisone(or Prednisolone)/Methotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in significantly better quality of life and less toxicity than standard dose Prednisone(or Prednisolone).
Phase:
Phase 3
Details
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Collaborator:
Canadian Institutes of Health Research (CIHR)
Treatments:
Methotrexate
Prednisolone
Prednisone